Quince Therapeutics (IRLA) Stock Price, News & Analysis

Company Overview

Quince Therapeutics is a clinical-stage biotechnology company focused on developing treatments for rare diseases with significant unmet medical needs. The company’s primary program is EryDex, an investigational therapy designed to deliver dexamethasone through a patient’s own red blood cells.

EryDex is being evaluated for the treatment of ataxia-telangiectasia, a rare inherited disorder that can cause progressive neurological impairment, immune-system problems and other serious complications. The company’s approach is intended to provide sustained exposure to dexamethasone while potentially reducing some of the side effects associated with conventional steroid treatment.

Quince Therapeutics was formerly known as Cortexyme, Inc. Before its strategic shift toward rare-disease programs, Cortexyme pursued therapies for neurodegenerative diseases, including Alzheimer’s disease. The company is headquartered in California and conducts its clinical development activities through research and medical collaborations. Information about its geographic commercial operations is limited because its principal product remains investigational.

Key Stats

• Today's Range: $26.72 to $30.23
• 50-Day Range: N/A
• 52-Week Range: $15.10 to $909.98
• Volume: 26,900 shs
• Average Volume: 192,418 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:IRLA
• CIK: N/A
• Web: www.quincetx.com
• Phone: (415) 910-5717
• Fax: N/A
• Employees: 38
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: N/A
• Beta: N/A